These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections. Nicolau DP Am J Manag Care; 2004 Oct; 10(12 Suppl):S381-8. PubMed ID: 15603247 [No Abstract] [Full Text] [Related]
6. Telithromycin--a ketolide antibiotic for the treatment of outpatients with community-acquired respiratory tract infections. Counts M Clin Nurse Spec; 2005; 19(3):121-3. PubMed ID: 15897765 [No Abstract] [Full Text] [Related]
7. Novel agents for the treatment of outpatient respiratory tract infections. Introduction. Pell DM Postgrad Med; 2002 Sep; 112(3 Suppl):5-6. PubMed ID: 19667592 [No Abstract] [Full Text] [Related]
8. [Selection between oral and injection routes of antibiotic therapy for respiratory infections based on clinical observations]. Kitsukawa K Nihon Naika Gakkai Zasshi; 1998 Feb; 87(2):254-8. PubMed ID: 9549320 [No Abstract] [Full Text] [Related]
9. Doxycycline in community acquired respiratory infections--a perspective of 1990's. Mahashur AA; Jaguste V J Assoc Physicians India; 1999 Mar; 47(3):326-31. PubMed ID: 10999130 [No Abstract] [Full Text] [Related]
10. Susceptibility of Chlamydia pneumoniae to oral agents commonly used in the treatment of respiratory infection. Beale AS; Masson ND J Antimicrob Chemother; 1994 Dec; 34(6):1072-4. PubMed ID: 7730224 [No Abstract] [Full Text] [Related]
11. Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs). Blasi F J Chemother; 2004 Apr; 16 Suppl 2():11-4. PubMed ID: 15255556 [No Abstract] [Full Text] [Related]
12. [Management of community-acquired lower respiratory infections. Management in the hospital]. Chidiac C Rev Mal Respir; 1999 Jan; 16 Suppl 3():S11-2. PubMed ID: 10088221 [No Abstract] [Full Text] [Related]
13. Comment on: Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data. Kirby A J Antimicrob Chemother; 2015 Nov; 70(11):3170. PubMed ID: 26157112 [No Abstract] [Full Text] [Related]
14. [Scientific evidence and global conception of empirical treatment of lower respiratory tract infections in the community]. Barberán J; Giménez MJ; Aguilar L; Prieto J Rev Esp Quimioter; 2004 Dec; 17(4):317-24. PubMed ID: 15696221 [No Abstract] [Full Text] [Related]
15. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data-authors' response. Zhanel GG; Wolter KD; Karlowsky JA J Antimicrob Chemother; 2015 Nov; 70(11):3170-1. PubMed ID: 26242414 [No Abstract] [Full Text] [Related]
16. Appropriate antibiotic therapy for community-acquired respiratory tract infections. Gerbino PP; Brixner D; Sbarbaro J; Nicolau D Manag Care Interface; 2005 Dec; 18(12):41-8. PubMed ID: 16405224 [TBL] [Abstract][Full Text] [Related]
17. [Cystic fibrosis: current therapy. Antibiotics]. Tamm M; Héritier F; Rappaz I; Schaad UB Schweiz Med Wochenschr Suppl; 2000; 122():33S-37S. PubMed ID: 12536469 [No Abstract] [Full Text] [Related]
18. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults. File TM Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S131-4. PubMed ID: 18029151 [TBL] [Abstract][Full Text] [Related]
19. [Guidelines for the epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults]. Höffken G; Lorenz J; Kern W; Welte T; Bauer T; Dalhoff K; Dietrich E; Ewig S; Gastmeier P; Grabein B; Halle E; Kolditz M; Marre R; Sitter H Dtsch Med Wochenschr; 2010 Feb; 135(8):359-65. PubMed ID: 20166002 [No Abstract] [Full Text] [Related]
20. [Clinical impact of antibiotic resistance in respiratory tract infections]. Klugman K Med Mal Infect; 2007 Nov; 37 Spec No 1():6-10. PubMed ID: 18376503 [No Abstract] [Full Text] [Related] [Next] [New Search]